Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma

Highlights • BSc2118 causes cell cycle arrest and induces apoptosis through p53 and caspase pathways in multiple myeloma. • BSc2118 inhibits multiple myeloma proliferation and angiogenesis in vitro and in vivo. • BSc2118 could partially overcome acquired bortezomib resistance in vitro , likely throu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer letters 2015-10, Vol.366 (2), p.173-181
Hauptverfasser: Zang, Meirong, Li, Zengjun, Liu, Lanting, Li, Fei, Li, Xin, Dai, Yun, Li, Wei, Kuckelkorn, Ulrike, Doeppner, Thorsten R, Hermann, Dirk M, Zhou, Wen, Qiu, Lugui, Jin, Fengyan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • BSc2118 causes cell cycle arrest and induces apoptosis through p53 and caspase pathways in multiple myeloma. • BSc2118 inhibits multiple myeloma proliferation and angiogenesis in vitro and in vivo. • BSc2118 could partially overcome acquired bortezomib resistance in vitro , likely through inhibiton of autophagy.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2015.06.011